Proteomic profiling of human cancer pseudopodia for the identification of anti-metastatic drug candidates

Sci Rep. 2018 Apr 11;8(1):5858. doi: 10.1038/s41598-018-24256-8.

Abstract

Cancer metastasis causes approximately 90% of all cancer-related death and independent of the advancement of cancer therapy, a majority of late stage patients suffers from metastatic cancer. Metastasis implies cancer cell migration and invasion throughout the body. Migration requires the formation of pseudopodia in the direction of movement, but a detailed understanding of this process and accordingly strategies of prevention remain elusive. Here, we use quantitative proteomic profiling of human cancer pseudopodia to examine this mechanisms essential to metastasis formation, and identify potential candidates for pharmacological interference with the process. We demonstrate that Prohibitins (PHBs) are significantly enriched in the pseudopodia fraction derived from cancer cells, and knockdown of PHBs, as well as their chemical inhibition through Rocaglamide (Roc-A), efficiently reduces cancer cell migration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Benzofurans / pharmacology
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Gene Knockdown Techniques
  • Humans
  • Neoplasm Metastasis / prevention & control*
  • Prohibitins
  • Proteomics / methods
  • Pseudopodia / drug effects
  • Pseudopodia / metabolism*
  • Repressor Proteins / antagonists & inhibitors
  • Repressor Proteins / genetics
  • Repressor Proteins / metabolism*

Substances

  • Antineoplastic Agents
  • Benzofurans
  • Prohibitins
  • Repressor Proteins
  • rocaglamide